View Future GrowthVaso 과거 순이익 실적과거 기준 점검 3/6Vaso의 수입은 연평균 -22.9%의 비율로 감소해 온 반면, Medical Equipment 산업은 수입이 연평균 13.6% 증가했습니다. 매출은 연평균 4.7%의 비율로 증가해 왔습니다. Vaso의 자기자본이익률은 6%이고 순이익률은 2%입니다.핵심 정보-22.94%순이익 성장률-23.27%주당순이익(EPS) 성장률Medical Equipment 산업 성장률8.90%매출 성장률4.66%자기자본이익률5.97%순이익률1.97%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트공시 • Aug 13Vaso Corporation to Report Q2, 2020 Results on Aug 14, 2020Vaso Corporation announced that they will report Q2, 2020 results at 2:00 PM, GMT Standard Time on Aug 14, 2020모든 업데이트 보기Recent updates공시 • Nov 20Nano-X Imaging Ltd. (NasdaqGM:NNOX) agreed to acquire VasoHealthcare IT Corp from Vaso Corporation (OTCPK:VASO) for $0.8 million.Nano-X Imaging Ltd. (NasdaqGM:NNOX) agreed to acquire VasoHealthcare IT Corp from Vaso Corporation (OTCPK:VASO) for $0.8 million on November 19, 2025. Under the terms of the proposed transaction, Nanox will acquire VHC IT for a total consideration of up to $0.8 million, consisting of a $0.2 million cash payment at closing and up to $0.6 million in performance-based earnout payments over a period of up to two years, contingent upon revenue retention targets with respect to existing customers. The transaction is expected to complete within a couple of weeks. Barley Snyder LLC acted as legal advisor to Vaso Corporation.공시 • Nov 06Vaso Corporation, Annual General Meeting, Dec 17, 2025Vaso Corporation, Annual General Meeting, Dec 17, 2025. Location: lever house, 390, park avenue, new york, ny 10022, United States공시 • Jan 13Vaso Corporation Elects Edgar Rios as Vice Chairman of Board of DirectorsVaso Corporation announced Edgar Rios was elected Vice Chairman of Board of Directors. Mr. Rios has served as an independent Director of Vaso since 2011. He will also continue in his role as Chairman of the Board’s Audit Committee.공시 • Jan 05Vaso Corporation Announces Executive ChangesVaso Corporation announced effective January 1, 2025, the board of directors appointed Jane Moen as its chief operating officer. Mr. Peter C. Castle, previously Chief Operating Officer, will continue in his capacity as President of the VasoTechnology Inc. Ms. Moen, age 45, has been a director of the Company since March 2020 and an executive officer of the Company since 2018. Ms. Moen has been President of the Vaso Diagnostics Inc. d/b/a VasoHealthcare, since June 2018 and will continue in that capacity. Effective January 1, 2025, Michael Beecher, previously Secretary, ceased serving in those role but will continue to be employed by the Company as a financial advisor. As a result, Jonathan Newton, previously Co-Chief Financial Officer and Treasurer of the Company, continues as the company’s sole Chief Financial Officer and Treasurer and was also appointed as the Secretary of the company.공시 • Dec 08Vaso Corporation (OTCPK:VASO) entered into a business combination agreement to acquire Achari Ventures Holdings Corp. I (NasdaqGM:AVHI) from Achari Sponsor Holdings I LLC and others for approximately $190 million in a reverse merger transaction.Vaso Corporation (OTCPK:VASO) entered into a business combination agreement to acquire Achari Ventures Holdings Corp. I (NasdaqGM:AVHI) from Achari Sponsor Holdings I LLC and others in a reverse merger transaction on September 12, 2023. Vaso Corporation entered into a business combination agreement to acquire Achari Ventures Holdings Corp. I from Achari Sponsor Holdings I LLC and others for approximately $190 million in a reverse merger transaction on December 6, 2023. Each share of common stock of Vaso issued and outstanding as of immediately prior to the Effective Time shall be automatically cancelled and extinguished and converted into the right to receive a number of shares of Achari’s common stock, in accordance with an exchange ratio set forth in the Business Combination Agreement and based on an equity value of Vaso of $176,000,000 and a price of $10 per share of the Achari Shares. Upon the closing of the Business Combination Agreement, it is anticipated that Achari will change its name to Vaso Holding Corp. Vaso common stock and warrants are expected to be listed on Nasdaq Capital Market ("Nasdaq") under the ticker symbols "VASO" and "VASOW", respectively. Vaso is led by Chief Executive Officer Jun Ma, who will continue to lead the combined company following the proposed business combination. If Agreement is terminated, then the non-terminating party shall pay to the terminating party an amount equal to $600,000. The obligations of Achari and Vaso to consummate the Business Combination is subject to various customary closing conditions, including the filing and effectiveness of a Registration Statement on Form S-4 (as amended or supplemented, the "Registration Statement") by Achari with the United States Securities and Exchange Commission ("SEC"), the filing and clearance by the SEC of a proxy statement by Vaso and the approval of the stockholders of both Achari and Vaso of the proposed business combination. The Boards of Directors of Vaso and Achari have each approved the Transaction. Ladenburg Thalmann & Co. Inc. is serving as financial, fairness opinion provider and capital markets advisor to Vaso. Timothy J. Kirby and Joshua A. Feiger of Katten Muchin Rosenman LLP acting as legal advisors to Achari and William Rosenstadt of Ortoli Rosenstadt LLP is acting as legal advisor to Vaso. Continental Stock Transfer & Trust Company will act as exchange agent to Achari.공시 • Oct 04Vaso Corporation, Annual General Meeting, Nov 15, 2022Vaso Corporation, Annual General Meeting, Nov 15, 2022, at 10:00 US Eastern Standard Time. Location: Grand Hyatt Tampa Bay Hotel, 2900 Bayport Drive, Tampa, Florida 33607 Florida United States Agenda: To discuss and approve election of two directors in class ii, to hold office until the 2025 annual meeting of stockholders; to discuss the ratification of the appointment of uhy llp as independent registered public accountants for the year ending December 31, 2022; and to discuss any other matters that properly come before the meeting.공시 • May 15Vaso Corporation announced delayed 10-Q filingOn 05/14/2021, Vaso Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Apr 01Vaso Corporation announced delayed annual 10-K filingOn 03/30/2021, Vaso Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • Aug 13Vaso Corporation to Report Q2, 2020 Results on Aug 14, 2020Vaso Corporation announced that they will report Q2, 2020 results at 2:00 PM, GMT Standard Time on Aug 14, 2020매출 및 비용 세부 내역Vaso가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:VASO 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Mar 2689252131 Dec 2589252130 Sep 2589351130 Jun 2587051131 Mar 2587149131 Dec 2487149130 Sep 2482047130 Jun 2481346131 Mar 2481346131 Dec 2381545130 Sep 23821244130 Jun 23821243131 Mar 23811242131 Dec 22791141130 Sep 2281741230 Jun 2279540231 Mar 2276640231 Dec 2176639230 Sep 2170437130 Jun 2169536131 Mar 2169136131 Dec 2070037130 Sep 2075139130 Jun 2076140131 Mar 2077141131 Dec 1976041130 Sep 1971-441130 Jun 1971-542131 Mar 1972-543131 Dec 1874-444130 Sep 1875-345130 Jun 1875-445131 Mar 1874-444131 Dec 1773-544130 Sep 1772-442130 Jun 1771-241131 Mar 1771-140131 Dec 1673139130 Sep 1675339030 Jun 1675438031 Mar 1667435131 Dec 1557431130 Sep 1548428130 Jun 15382251양질의 수익: VASO는 $3.8M 규모의 큰 일회성 손실이 있어 31st March, 2026까지 지난 12개월 재무 결과에 영향을 미쳤습니다.이익 마진 증가: VASO의 현재 순 이익률 (2%)은 지난해 (1.2%)보다 높습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: VASO의 수익은 지난 5년 동안 연평균 22.9% 감소했습니다.성장 가속화: 지난 1년간 VASO 의 수익 증가율(67.5%)은 연간 평균(-22.9%)을 초과합니다.수익 대 산업: VASO의 지난 1년 수익 증가율(67.5%)은 Medical Equipment 업계의 14.8%를 상회했습니다.자기자본이익률높은 ROE: VASO의 자본 수익률(6%)은 낮음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YHealthcare 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 08:31종가2026/05/22 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Vaso Corporation는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Aug 13Vaso Corporation to Report Q2, 2020 Results on Aug 14, 2020Vaso Corporation announced that they will report Q2, 2020 results at 2:00 PM, GMT Standard Time on Aug 14, 2020
공시 • Nov 20Nano-X Imaging Ltd. (NasdaqGM:NNOX) agreed to acquire VasoHealthcare IT Corp from Vaso Corporation (OTCPK:VASO) for $0.8 million.Nano-X Imaging Ltd. (NasdaqGM:NNOX) agreed to acquire VasoHealthcare IT Corp from Vaso Corporation (OTCPK:VASO) for $0.8 million on November 19, 2025. Under the terms of the proposed transaction, Nanox will acquire VHC IT for a total consideration of up to $0.8 million, consisting of a $0.2 million cash payment at closing and up to $0.6 million in performance-based earnout payments over a period of up to two years, contingent upon revenue retention targets with respect to existing customers. The transaction is expected to complete within a couple of weeks. Barley Snyder LLC acted as legal advisor to Vaso Corporation.
공시 • Nov 06Vaso Corporation, Annual General Meeting, Dec 17, 2025Vaso Corporation, Annual General Meeting, Dec 17, 2025. Location: lever house, 390, park avenue, new york, ny 10022, United States
공시 • Jan 13Vaso Corporation Elects Edgar Rios as Vice Chairman of Board of DirectorsVaso Corporation announced Edgar Rios was elected Vice Chairman of Board of Directors. Mr. Rios has served as an independent Director of Vaso since 2011. He will also continue in his role as Chairman of the Board’s Audit Committee.
공시 • Jan 05Vaso Corporation Announces Executive ChangesVaso Corporation announced effective January 1, 2025, the board of directors appointed Jane Moen as its chief operating officer. Mr. Peter C. Castle, previously Chief Operating Officer, will continue in his capacity as President of the VasoTechnology Inc. Ms. Moen, age 45, has been a director of the Company since March 2020 and an executive officer of the Company since 2018. Ms. Moen has been President of the Vaso Diagnostics Inc. d/b/a VasoHealthcare, since June 2018 and will continue in that capacity. Effective January 1, 2025, Michael Beecher, previously Secretary, ceased serving in those role but will continue to be employed by the Company as a financial advisor. As a result, Jonathan Newton, previously Co-Chief Financial Officer and Treasurer of the Company, continues as the company’s sole Chief Financial Officer and Treasurer and was also appointed as the Secretary of the company.
공시 • Dec 08Vaso Corporation (OTCPK:VASO) entered into a business combination agreement to acquire Achari Ventures Holdings Corp. I (NasdaqGM:AVHI) from Achari Sponsor Holdings I LLC and others for approximately $190 million in a reverse merger transaction.Vaso Corporation (OTCPK:VASO) entered into a business combination agreement to acquire Achari Ventures Holdings Corp. I (NasdaqGM:AVHI) from Achari Sponsor Holdings I LLC and others in a reverse merger transaction on September 12, 2023. Vaso Corporation entered into a business combination agreement to acquire Achari Ventures Holdings Corp. I from Achari Sponsor Holdings I LLC and others for approximately $190 million in a reverse merger transaction on December 6, 2023. Each share of common stock of Vaso issued and outstanding as of immediately prior to the Effective Time shall be automatically cancelled and extinguished and converted into the right to receive a number of shares of Achari’s common stock, in accordance with an exchange ratio set forth in the Business Combination Agreement and based on an equity value of Vaso of $176,000,000 and a price of $10 per share of the Achari Shares. Upon the closing of the Business Combination Agreement, it is anticipated that Achari will change its name to Vaso Holding Corp. Vaso common stock and warrants are expected to be listed on Nasdaq Capital Market ("Nasdaq") under the ticker symbols "VASO" and "VASOW", respectively. Vaso is led by Chief Executive Officer Jun Ma, who will continue to lead the combined company following the proposed business combination. If Agreement is terminated, then the non-terminating party shall pay to the terminating party an amount equal to $600,000. The obligations of Achari and Vaso to consummate the Business Combination is subject to various customary closing conditions, including the filing and effectiveness of a Registration Statement on Form S-4 (as amended or supplemented, the "Registration Statement") by Achari with the United States Securities and Exchange Commission ("SEC"), the filing and clearance by the SEC of a proxy statement by Vaso and the approval of the stockholders of both Achari and Vaso of the proposed business combination. The Boards of Directors of Vaso and Achari have each approved the Transaction. Ladenburg Thalmann & Co. Inc. is serving as financial, fairness opinion provider and capital markets advisor to Vaso. Timothy J. Kirby and Joshua A. Feiger of Katten Muchin Rosenman LLP acting as legal advisors to Achari and William Rosenstadt of Ortoli Rosenstadt LLP is acting as legal advisor to Vaso. Continental Stock Transfer & Trust Company will act as exchange agent to Achari.
공시 • Oct 04Vaso Corporation, Annual General Meeting, Nov 15, 2022Vaso Corporation, Annual General Meeting, Nov 15, 2022, at 10:00 US Eastern Standard Time. Location: Grand Hyatt Tampa Bay Hotel, 2900 Bayport Drive, Tampa, Florida 33607 Florida United States Agenda: To discuss and approve election of two directors in class ii, to hold office until the 2025 annual meeting of stockholders; to discuss the ratification of the appointment of uhy llp as independent registered public accountants for the year ending December 31, 2022; and to discuss any other matters that properly come before the meeting.
공시 • May 15Vaso Corporation announced delayed 10-Q filingOn 05/14/2021, Vaso Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Apr 01Vaso Corporation announced delayed annual 10-K filingOn 03/30/2021, Vaso Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • Aug 13Vaso Corporation to Report Q2, 2020 Results on Aug 14, 2020Vaso Corporation announced that they will report Q2, 2020 results at 2:00 PM, GMT Standard Time on Aug 14, 2020